-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TERN-701 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-701 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TERN-701 in Chronic Myelocytic Leukemia (CML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MyMD-1 in Sarcopenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MyMD-1 in Sarcopenia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MyMD-1 in Sarcopenia Drug Details: MyMD-1 (Isomyosamine) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCB-71 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LCB-71 in Solid Tumor Drug Details: LCB-71 (ABL-202) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCB-71 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LCB-71 in Mantle Cell Lymphoma Drug Details: LCB-71 (ABL-202) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saracatinib Difumarate in Psychosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saracatinib Difumarate in Psychosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saracatinib Difumarate in Psychosis Drug Details: Saracatinib difumarate (AZD-0530) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCB-71 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LCB-71 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCB-71 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LCB-71 in Diffuse Large B-Cell Lymphoma Drug Details: LCB-71...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCB-71 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LCB-71 in B-Cell Non-Hodgkin Lymphoma Drug Details: LCB-71 (ABL-202) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCB-71 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LCB-71 in Triple-Negative Breast Cancer (TNBC) Drug Details: LCB-71...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target BCMA And CD19 For Blood Cancers And Systemic Lupus Erythematosus in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target BCMA And CD19 For Blood Cancers And Systemic Lupus Erythematosus in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10...